Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which includes 1,999,999 common shares from the full exercise of the underwriters’ over-allotment option to purchase additional shares. The common shares are listed on the Nasdaq Global Market under the symbol “CVAC.” 

CureVac is a global clinical-stage biopharmaceutical company in the field of messenger RNA (mRNA) technology with expertise in developing and optimizing this versatile molecule for medical purposes. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.

The Davis Polk corporate team included partners Richard D. Truesdell Jr. and Leo Borchardt, counsel Jeffrey S. Ramsay and Alain Kuyumjian and associate Gil Savir. The tax team included partner Patrick E. Sigmon. The intellectual property and technology transactions team included partner David R. Bauer and associate Hilary Smith. The executive compensation team included partner Kyoko Takahashi Lin and associate Melissa Esposito. Members of the Davis Polk team are based in the New York and London offices.

Copy link to share post